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The role dopamine plays in decision-making has important theoretical, empirical and clinical implications. Here, we examined its
precise contribution by exploiting the lesion deﬁcit model afforded by Parkinson’s disease. We studied patients in a two-stage
reinforcement learning task, while they were ON and OFF dopamine replacement medication. Contrary to expectation, we found
that dopaminergic drug state (ON or OFF) did not impact learning. Instead, the critical factor was drug state during the
performance phase, with patients ON medication choosing correctly signiﬁcantly more frequently than those OFF medication.
This effect was independent of drug state during initial learning and appears to reﬂect a facilitation of generalization for learnt
information. This inference is bolstered by our observation that neural activity in nucleus accumbens and ventromedial prefrontal
cortex, measured during simultaneously acquired functional magnetic resonance imaging, represented learnt stimulus values
during performance. This effect was expressed solely during the ON state with activity in these regions correlating with better
performance. Our data indicate that dopamine modulation of nucleus accumbens and ventromedial prefrontal cortex exerts a
speciﬁc effect on choice behaviour distinct from pure learning. The ﬁndings are in keeping with the substantial other evidence
that certain aspects of learning are unaffected by dopamine lesions or depletion, and that dopamine plays a key role in
performance that may be distinct from its role in learning.
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Introduction
Dopamineis strongly implicated in rewardsignalling, playing a central
role in reward learning in animals (Wise and Rompre, 1989; Schultz
et al., 1997; Schultz, 1998; Wise, 2004; Bayer and Glimcher, 2005)
and humans (Pessiglione et al., 2006). Accumulating evidence from
pharmacological interventions in healthy subjects (Pessiglione et al.,
2006) and patients with Parkinson’s disease studied ON and OFF
medication (Frank et al., 2004, 2007b) indicate that manipulating
dopamine neurotransmission in humans inﬂuences reward-related
reinforcement learning and decision-making. An assumption arising
fromthesedataisthatdopamineexertsadirecteffectoninstrumental
learning,a formof learning that links actions and their outcomes. At a
mechanistic level, activity in dopaminergic neurons express a predic-
tion error believedto mediate learning and updating the reward value
of predictive stimuli (Schultz et al., 1997). The idea that prediction
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patterns within the dopaminergic system is supported by a substantial
body of experimental work across a range of species (Haber and
Knutson, 2010).
However, the functions of dopamine are known to extend
beyond reinforcement learning. First, considerable evidence points
to a contribution to the control of Pavlovian approach behaviour
(Ikemoto and Panksepp, 1999; Parkinson et al., 2002; Day and
Carelli, 2007) as well as in motivational engagement and vigour
(Ahlenius et al., 1977; Beninger and Phillips, 1981; Berridge and
Robinson, 1998; McClure et al., 2003; Niv, 2007; Niv et al., 2007;
Bardgett et al., 2009; Lex and Hauber, 2010; Boureau and Dayan,
2011). These inﬂuences are distinct from learning (Yin et al., 2008),
even in cases where they arise from a signal that actually reports a
prediction error (McClure et al., 2003). Secondly, many aspects of
appetitive learning can progress normally in the absence of dopa-
mine, most dramatically in the case of genetically engineered
dopamine-deﬁcient mice (Palmiter, 2008). Thirdly, a number of
previous studies that investigated the effect of dopamine in
humans could not easily distinguish between action learning and
action performance (Frank et al., 2004, 2007b; Pessiglione et al.,
2006). Consequently, in assessing dopamine’s impact on behaviour,
it is necessary to distinguish inﬂuences on learning from inﬂuences
on the modulation of the expression of learning, i.e. an effect on
actual choice behaviour or performance.
Parkinson’s disease is a common neurological disorder character-
ized by neuronal loss in the substantia nigra (Edwards et al., 2008),
which leads to depleted levels of striatal dopamine (Koller and
Melamed, 2007). Parkinson’s disease results in deﬁcits across several
cognitive domains, including probabilistic learning and classiﬁcation
tasks (Knowlton et al., 1996; Graef et al., 2010), with dopamine
replacement therapy having distinct effects on these behaviours.
For example, when Parkinson’s disease patients are OFF dopamine
replacement therapy, it is reported that their expression of learning
from positive feedback is impaired (Frank et al., 2004, 2007b), while
when ON dopamine replacement therapy they show impaired per-
formance in learning from negative outcomes (Frank et al., 2004;
Bodi et al., 2009). This behavioural pattern has been attributed to
increased levels of striatal dopamine when patients are ON medica-
tion boosting prediction error signals resulting in enhanced learning
from positive outcomes. In contrast, a prevention of dips in dopa-
minergic activity, as occurs with omission of expected outcomes, is
suggested to worsen learning from negative outcomes (Frank et al.,
2004; Frank, 2007b; Maia and Frank, 2011).
Here, we sought to dissociate dopaminergic effects on learning
from effects on choice (performance) by acquiring neuroimaging
data during a reinforcement learning task in patients with
Parkinson’s disease. We employed a two-stage learning task that
involves separate phases of (i) acquisition and (ii) a subsequent
performance testing involving generalization of learning. This
task has previously been shown to provide an effective means
of examining the neural mechanisms underlying cognitive deﬁcits
in Parkinson’s disease (Frank et al., 2004, 2007b). These previous
studies focused on learning, while here we also probed the effect
of dopaminergic status (ON medication, and OFF medication) on
test ‘performance’, i.e. on the expression of learning during
behavioural extinction. Crucially, this dissociation between learning
and performance has not been explicitly explored in previous
human investigations.
Materials and methods
The study and its procedures were approved by the National Research
Ethics Service, The Joint UCL/UCLH Committees on the Ethics of
Human Research (Committee A).
Participants
Fourteen early-to-moderate stage (Hoehn and Yahr stage: mean 1.69,
SE 0.26) patients with idiopathic Parkinson’s disease (10 males) (as per
UK Brain Bank criteria) aged between 44 and 81 years (mean 61.8
years, SE 3.3 years) participated in and completed the study. Patients
were recruited from the movement disorder clinic at the National
Hospital for Neurology and Neurosurgery.
We obtained written informed consent from all subjects and trans-
port costs were reimbursed.
Subjects were interviewed for psychiatric and neurological history as
well as current and past medication. They were also examined by a
clinician and asked to complete several questionnaires, including a
health questionnaire, a Mini-Mental State Examination and an impulse
control disorder screening questionnaire (Supplementary Table 1).
One subject had difﬁculty understanding the task demands and
adopted an incorrect strategy for stimulus selection, whereby he
explicitly believed the incorrect stimulus to be correct and continued
to select it despite ongoing negative feedback resulting in signiﬁcantly
worse than chance performance. Data from this subject are not
included in any analyses. Another subject was excluded from the ima-
ging analysis due to an incidental ﬁnding of abnormally large ven-
tricles, compromising normalization of this data set to a standard
coordinate space. Hence, 13 subjects were analysed behaviourally
and 12 subjects were analysed in the functional MRI study.
Twelve of the subjects were right-handed and one was left-handed.
All were ﬂuent English speakers. The duration of Parkinson’s disease
varied from 1 to 10 years from the time of initial diagnosis (mean 4.9
years, SE 0.96 years). Subjects had no history of other major
neurological or psychiatric disease. Patients were all on levodopa/car-
bidopa combinations; eight patients were also on dopamine agonists;
total daily dose of levodopa/carbidopa varied from 50/12.5mg to
1000/255mg (mean 400/100mg, SE 74.4/18.6mg) (Supplementary
Table 2). We did not recruit patients on trihexyphenidyl, benzhexol or
high-dose tolterodine due to possible confounding effects of high-dose
anti-cholinergic medication, or patients on amantadine due to its effect
on multiple neuromodulators.
Stimuli
We used a version of the generalization task introduced by Frank et al.
(2004, 2007b). Stimuli consisted of Hiragana symbols presented in
white fonts on a black background where each stimulus had a differ-
ent probability of being correct when selected. These probabilities
ranged from 80% to 20%. In the ﬁrst, or acquisition, stage of the
task, the symbols were paired to form three sets: the 80% stimulus
was paired with the 20% stimulus; the 70% stimulus was paired with
the 30% stimulus and the 60% stimulus with the 40% stimulus. The
sets were presented in a randomized order. In the second, or perform-
ance phase, along with all the training pairings, the best stimulus
(the one with 80% chance of being correct) and the worst stimulus
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novel pairings with all the other stimuli (Fig. 1).
Procedure
Overview
Each patient participated in three separate sessions on different days,
which were a minimum of 1 week apart (i.e. a within-subject design).
Each session involved different Hiragana symbols (Fig. 1). All patients
performed the task in three different drug states (Supplementary Table
3): acquisition and performance in the ON state (ON–ON), acquisition
and performance in the OFF state (OFF–OFF) and acquisition of the
stimulus contingencies in the OFF state but performance in the ON
medication state (OFF–ON). The order of the different drug states in
which patients performed the task was randomized. The OFF state in
two of the conditions was achieved by a minimum of 12h withdrawal
from all dopaminergic medication and omission of all slow release
preparations for a minimum of 18h. On the remaining day
(ON–ON), patients were asked to take their morning dopaminergic
medication as usual. We were unable to test patients in the
ON–OFF state, i.e. acquisition in the ON state and performance in
the OFF state, due to the half-life of levodopa/carbidopa combin-
ations, which would require a minimum of 7.5h to be metabolized
and excreted resulting in too long an interval between the acquisition
and performance phases. All patients were tested at similar times in
the morning to equalize washout times and to control for diurnal
symptom ﬂuctuations.
To familiarize subjects with the structure of the task, we undertook
a short practice block before the ﬁrst scanning session. During the
practice session, patients worked on an identical task as in the main
study except for the fact they were presented with different Hiragana
symbols. The main session began with two functional scans (Scans 1
and 2, acquisition sessions). Most subjects completed a third acquisi-
tion session on a laptop. In OFF–ON condition, patients took their
medication following this training. All patients then waited for
45–60min before undergoing a third functional scanning session
(Scan 3, performance session) for performance testing.
On one of the 3 days, after the training and performance stages
were complete, the patients also underwent a structural scan, a
Mini-Mental State Examination and completed questionnaires as
detailed above.
Acquisition phase of the task: Scans 1 and 2
Scan sessions 1 and 2 (acquisition phase of the task), lasted 16min,
and consisted of 120 trials of 8s each. On each trial, two Hiragana
characters appeared on the screen side by side, presented via a mirror
mounted on the head coil. Subjects’ task was to select one of the
characters on each trial by pressing either the right or the left key
on a button box. The stimuli remained on the screen for 4s, followed
Figure 1 Task. Stimuli consisted of Hiragana symbols which were presented in white fonts on a black background. Each stimulus had a
different probability of being correct when selected. In the ﬁrst, or acquisition stage of the task, symbols were paired to form three ‘training
pairs’ that remained the same throughout this phase: the 80% stimulus was paired with the 20% stimulus (highlighted for illustration
purposes with a red border); the 70% stimulus was paired with the 30% stimulus (blue border) and the 60% stimulus with the 40% stimulus
(green border). Subjects selected the left or right stimulus by button presses and, during the acquisition phase, also received information
about the outcome (correct/incorrect). In the second, or performance phase, along with all the training pairings, the best stimulus (the one
with 80% chance of being correct) and the worst stimulus (the one with only 20% chance of being correct) were presented in novel pairings
with all the other stimuli. During this phase subjects did not receive information about the outcome of their choice. During this phase,
subjects were also presented again with the three sets of ‘training pairs’, which were interspersed with the novel pairs.
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The likelihood of being correct or incorrect was probabilistically deter-
mined for each stimulus (see above). If subjects did not respond within
4s that the stimuli were on the screen the message ‘no key pressed’
was presented and the trial was excluded from the analysis. A ﬁxation
cross was presented for 2s during the intertrial interval.
Performance phase of the task: Scan 3
Scanning session 3 (performance phase) was 10-min long and con-
sisted of 110 trials of 6s each. Similar to the acquisition phase, two
Hiragana characters were presented side by side on each trial and
subjects had to select one of the characters by pressing either the
right or the left key. As before, characters remained on screen for
4s. This time subjects did not receive feedback after making a re-
sponse and the trial instead progressed immediately to the presenta-
tion of a ﬁxation cross during the 2s intertrial interval.
Importantly, in addition to the stimulus pairs used during training
(80% with 20%; 70% with 30% and 60% with 40%), the symbols
were shown in eight novel pairings. Four of the pairings had the ‘best’
stimulus paired with all other stimuli (80% with 70%; 80% with 60%;
80% with 40% and 80% with 30%), and the other four pairings
compared the ‘worst’ stimulus to all other stimuli (20% with 70%;
20% with 60%; 20% with 40% and 20% with 30%). All pairs were
presented 10 times each in randomized order, resulting in 110 pairs
overall (Fig. 1).
Magnetic resonance imaging
The study was conducted at the Wellcome Trust Centre for
Neuroimaging at University College London using a 3 T (Siemens
TRIO) scanner equipped with a Siemens 12-channel phased array
head coil. Anatomical images were acquired using modiﬁed equilibrium
Fourier transform T1 gradient echo scans, which were followed by
1-mm thick axial slices parallel to the anterior commissure–posterior
commissure plane. Functional scans used a gradient echo sequence;
repetition time, 2.04s; echo time 30ms; ﬂip angle 90; matrix size
64  64; ﬁeld of view 192mm; slice thickness, 2mm. A total of 30
axial slices were sampled. The in-plane resolution was 2  2mm.
Functional imaging data were analysed using statistical parametric
mapping software (SPM5; Wellcome Trust Centre for Neuroimaging;
http://www.ﬁl.ion.ucl.ac.uk/spm). During preprocessing, images were
realigned with the ﬁrst volume (after discarding six volumes to allow
for T1 equilibration effects), and unwarped. For each subject, the mean
functional image was coregistered to a high resolution T1 structural
image. This image was then spatially normalized to standard Montreal
Neurological Institute (MNI) space using the ‘uniﬁed segmentation’
algorithm available within SPM5 (Ashburner and Friston, 2005) with
the resulting deformation ﬁeld applied to the functional imaging data.
These data were then spatially smoothed using an isotropic 6-mm
full-width half-maximum Gaussian kernel.
Data analysis
Behavioural analysis
Acquisition sessions 1–3
All subjects reached at least 65% accuracy for the easiest pairing or
after completion of three acquisition sessions had a minimum accuracy
of 60% over all training pairs before proceeding to the performance
phase. Accuracy levels in the acquisition phase were then separately
computed for each drug state by averaging the overall accuracy across
all acquisition sessions on that day. Accuracy was deﬁned as
percentage of trials on which the correct stimulus, i.e. the stimulus
with the highest probabilistic contingency in each training pair was
selected. We then compared overall accuracy during acquisition in
the ON condition to overall accuracy in the two OFF medication
states using paired t-tests and a linear mixed model to detect differ-
ences in accuracy in the acquisition phase between different drug
states. We also tested for differences in the acquisition rate between
the different drug states by comparing learning rates in a reinforce-
ment learning model (see below). For this test, we individually ﬁtted
the parameters of the reinforcement learning model to subjects’
choices in the ON and OFF medication condition, comparing the re-
sulting learning rates using a paired t-test.
Performance session
Data from the performance session were separated into trials in which
the ‘best’ stimulus (80% chance of being correct) was presented, and
trials in which the ‘worst’ stimulus (20% chance of being correct) was
presented. We calculated the percentage of times subjects picked the
best stimulus and the percentage of times the subjects avoided the
worst stimulus in these novel pairings and tested for any differences in
performance between the different medication conditions.
Reinforcement learning model
We used a simple prediction error-based reinforcement learning model
(Sutton and Barto, 1998) to estimate a trial-by-trial measure of stimu-
lus value, and thus an outcome prediction error  deﬁned as the dif-
ference between the actual observed outcome R (correct/
incorrect = 1/0) and the current expected value of the chosen
stimulus.
For each pair of stimuli A and B, the model estimates the expected
values of choosing A, (QA) and choosing B (QB), on the basis of in-
dividual sequences of choices and outcomes. The expected values
were set to zero before learning. After every trial t40 the value of
the chosen stimulus (e.g. ‘A’) was updated according to the rule
QA(t +1 )=QA(t)+  (t). The outcome prediction error is the dif-
ference between the actual and the expected outcome,
(t)=R(t)  QA(t) with the actual outcome being either ‘Correct’ or
‘Incorrect’ (1 or 0). Values of stimuli that were not shown on a trial
were not updated.
Given the expected values, the probability (or likelihood) of the
observed choice was estimated using the softmax rule:
PA(t) = exp[QA(t)/]/{exp[QA(t)/] + exp[QB(t)/]}. The parameters 
(learning rate) and  (temperature) were adjusted to maximize the
likelihood of the actual choices under the model, for all subjects.
Trial-by-trial outcome prediction errors estimated by the model were
then used as parametric regressors in the imaging data.
We also considered an alternative reinforcement learning model,
which allowed for separate learning rates 
+ on positive updates
(increasing the predicted value) and 
 on negative updates
(decreasing the predicted value). We then compared model likelihoods
of the models with separate learning rates and the original reduced
model on an individual subject level using Bayesian Information
Criterion (BIC), which corrects for the different complexity in models
(smaller values indicate better ﬁt) (Schwarz, 1978), and population
level using Bayesian model comparison (Stephan et al., 2009).
Functional magnetic resonance imaging: whole-brain
general linear model parametric analysis
Acquisition session
Functional MRI time series were regressed onto a composite general
linear model containing four regressors: trial onset time (the
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response time and ﬁxation cross presentation time. The outcome onset
was parametrically modulated by the prediction error as estimated by
the reinforcement learning model. We also composed another general
linear model in which there were four regressors: correct trial onset
time, incorrect trial onset time, motor response time and ﬁxation cross
presentation time. The actual value of the chosen cue in each trial was
entered as a parametric modulator of the two trial onset regressors.
Performance session
Four regressors were entered into the functional MRI model: correct
trial onset time, incorrect trial onset time, motor response time and
ﬁxation cross presentation time. The actual value of the chosen cue in
each trial was entered as a parametric modulator of the two trial onset
regressors.
The regressors were convolved with the canonical haemodynamic
response function, and low frequency drifts were excluded with a
high-pass ﬁlter (128-s cut-off). Short-term temporal autocorrelations
were modelled using an autoregressive [AR(1)] process. Motion cor-
rection regressors estimated from the realignment procedure were
entered as covariates of no interest. Statistical signiﬁcance was as-
sessed using linear compounds of the regressors in the general linear
model, generating statistical parametric maps of t-values across the
brain for each subject and contrast of interest. These contrast
images were then entered into a second-level random-effects analysis
using a one-sample t-test against zero.
Anatomical localization was carried out by overlaying the t-maps on
a normalized structural image averaged across subjects, and with ref-
erence to an anatomical atlas (Naidich et al., 2009). All coordinates are
reported in MNI space (Mazziotta et al., 1995).
Region of interest analysis
We extracted data for all region of interest analyses using a
cross-validation leave-one-out procedure: we re-estimated our main
second-level analysis 12 times, always leaving out one subject.
Starting at the peak voxel for the chosen cue value signal in ventro-
medial prefrontal cortex and nucleus accumbens, which was identiﬁed
by looking over all correct trials (in both the ON and OFF drug states),
we selected the nearest maximum in these cross-validation
second-level analyses. Using that new peak voxel, we then extracted
the data from the left-out subject and calculated a representative time-
course for each region of interest as ﬁrst eigenvariate from data in all
voxels within a 4-mm sphere around that peak. We then performed a
small volume correction on the striatal activations in the putamen
using an anatomical region of interest deﬁned according to the
Talairach Daemon atlas (Lancaster et al., 1997) using the SPM WFU
PickAtlas tool (Maldjian et al., 2003).
Results
We used a within-subject design to study a single group of pa-
tients with Parkinson’s disease [early-to-moderate stage (Hoehn
and Yahr stage: mean 1.69, SE 0.26)] in a generalization task
introduced by Frank et al. (2004, 2007b) in three separate drug
states (Fig. 1). We employed a within-subject design given the
inherent difﬁculty in accurately matching patients with
Parkinson’s disease with different disease severity. We also believe
that this design allowed us to minimize and control, as far as
possible, for individual cognitive and genetic differences that
may exist in our cohort, allowing us to look at the within-subject
effects of drug on behaviour. In parallel with our behavioural
analysis, we also acquired neural data using functional MRI.
Thus, this design enabled us to explore the effect of dopamine
on behaviour and on the brain by testing patients in three differ-
ent drug states: acquisition and performance ON medication; ac-
quisition and performance OFF medication and acquisition in an
OFF medication state and performance in an ON medication state.
The inclusion of the latter condition speciﬁcally enabled us to
probe whether dopamine’s effects are expressed during task ac-
quisition (learning) or task performance.
Acquisition phase
Behavioural results
At the end of the acquisition phase, average choice accuracy on
the training pairs did not differ between groups across the differ-
ent drug states [paired t-tests: comparing ON–ON with OFF–ON:
t(1,12) = 0.15, P = 0.87; comparing ON–ON with OFF–OFF:
t(1,12) = 0.095, P = 0.92; comparing OFF–ON with OFF–OFF:
t(1,12) = 0.079, P = 0.93] (Supplementary Table 4). Similarly,
we found no signiﬁcant difference in learning rates between pa-
tients when they were in an OFF compared to ON medication
state [ON: mean 0.25, SE 0.02; OFF: mean 0.24, SE 0.01;
paired t-test t(1,12) = 0.117, P = 0.90] (Supplementary Table 5),
or in the number of sessions required to reach criteria [ON: mean
1.23, SE 0.12; OFF: mean 1.38, SE 0.16 paired t-test
t(1,12) = 0.69, P = 0.50]. When the three types of training
pairs were examined separately, there were no differences in
choice accuracy between the different drug states. When we com-
pared log evidences from a learning model with separate learning
rates for positive and negative updates (posneg) with a single
learning rate model (single), we found that the more complex
model did not explain behaviour any better than the simple
model (average BICsingle = 260.9 versus BICposneg = 261.4; poster-
ior probability Psingle = 0.72; exceedance probability single versus
posneg model P40.99). Thus, subjects’ behaviour could not be
explained better with separate learning rates for positive and
negative updating.
Neuroimaging data
Here, we examined brain responses that correlated with outcome
prediction errors computed from a reinforcement learning model,
ﬁt to subjects’ behaviour during the acquisition phase. We found
that bilateral responses in the striatum (central coordinates right
putamen x = 26, y =0 ,z = 4; left putamen x = 28, y = 12,
z = 2) (Fig. 2) strongly correlated with reward prediction errors
[small volume corrected using anatomical region of interest for
false discovery rate (FDR); left putamen P = 0.007, right putamen
P = 0.006], consistent with many previous results (McClure et al.,
2003; O’Doherty et al., 2003; Schonberg et al., 2010). However,
similar to our behavioural ﬁndings, we found no differences in
prediction error-related brain activation between the different
drug states during acquisition [paired t-test ON compared with
OFF: t(1,11) = 0.076, P = 0.46] (see Supplementary Table 6
for a whole-brain activation table for prediction error-related ac-
tivity across all drug conditions). We separately examined neural
responses to positive and negative prediction errors but did not
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t-tests comparing positive prediction errors ON compared with
OFF: t(1,11) = 0.083, P = 0.42; and comparing negative predic-
tion errors ON with OFF: t(1,11) = 0.051, P = 0.614]. Perhaps
most surprisingly, at the time of cue onset, we did not observe any
correlation between brain activity and the value of the chosen cue
in any of the drug states.
Performance phase
Behavioural results
In the performance phase, after patients had acquired the task
contingencies, along with all the training pairings, we presented
the best (the one with 80% chance of being correct) and worst
stimulus (the one with only 20% chance of being correct) in novel
pairings with all the other stimuli (Fig. 1). We found that patients
ON their dopamine replacement therapy performed signiﬁcantly
better than patients OFF dopamine replacement therapy [main
effect comparing accuracy of the mean of ON–ON/OFF–ON with
OFF–OFF, paired t-test, t(1,12) = 2.8, P = 0.01]. Crucially, a separ-
ate examination of the three drug states revealed a main effect of
drug on performance but not on acquisition (Fig. 3A). Subjects who
acquired the contingencies in an OFF medication state and received
their dopamine replacement therapy after the acquisition phase, but
before the performance phase, had the same level of overall accur-
acy as subjects who both acquired the contingencies ON medica-
tion and performed ON medication [paired t-test comparing ON–
ON with OFF–ON, t(1,12) = 0.03, P = 0.97]. Both the ON–ON
and OFF–ON groups were signiﬁcantly more accurate than the
OFF–OFF group [paired t-test comparing ON–ON with OFF–OFF,
t(1,12) = 2.17, P = 0.05; and comparing OFF–ON with OFF–OFF,
t(1,12) = 2.28 P = 0.04]. A mixed effects linear model showed a
signiﬁcant effect of drug state on performance accuracy at the
performance phase [F(1,36) = 5.38, P = 0.02] but not at the
acquisition phase [F(1,36) = 0.002, P =0 . 9 6 ] .
Inadditiontothenovelpairings,wealsopresentedsubjectswiththe
threestimuluspairsonwhichtheyhadbeentrainedduringacquisition.
Interestingly,wefoundnodifferenceinaccuracylevelsonthesetrain-
ing pairs across the different drug states [paired t-tests comparing
ON–ON with OFF–ON, t(1,12) = 1.36, P = 0.19; comparing ON–
ON with OFF–OFF, t(1,12) = 0.64, P = 0.52; comparing OFF–ON
with OFF–OFF t(1,12) = 1.26, P = 0.23] (Fig. 3B), even when the
three types of training pairs were examined separately. Indeed,
there was no difference in the accuracies for training pairs versus
novelpairs inON–ON orOFF–ONdrugstates[paired t-testscompar-
ing training pair accuracy with novel pair accuracy in ON–ON,
t(1,12) = 0.61, P = 0.55 and OFF–ON drug states, t(1,12) = 1.75,
P = 0.10]. However, as expected, in the OFF–OFF drug state, accur-
acy for training pairs was signiﬁcantly higher than for novel pairs
[t(1,12) = 2.28,P = 0.04].Notethatourresultscannotbeexplained
byafasterextinctioneffectinthepatientswhentheywereOFFdopa-
mine replacement therapy. An effect of this sort would predict an
overall gradual performance decrement over time. Instead, we
found that patients OFF medication maintained their performance in
the training pairs, which were randomly interspersed with the novel
pairs, throughout the test session. One difference between our study
andthatofFranketal.(2004,2007b)isthatinourstudytherewasan
added time delay between acquisition and transfer, whilst L-DOPA
took effect. Since dopamine inﬂuences processes such as working
memory (Sawaguchi and Goldman-Rakic, 1991; Watanabe et al.,
1997;Fuster,2001;StussandKnight,2002)andenhancingdopamine
signalling will have had an effect on these processes (Sawaguchi,
2001; Wang et al., 2004; Gibbs and D’Esposito, 2005; Cools and
D’Esposito, 2011), one could argue that the poor generalization in
the OFF group could stem from the delay. However, we believe this
isunlikelygivenevidencethattheOFFgroupperformedjustaswellas
the ON group on training pairs.
Figure 2 Prediction error-related activity during acquisition. (A) Brain activity in putamen correlated with magnitude of outcome
prediction errors across all trials during the acquisition phase. Activations are thresholded at P50.001 uncorrected. (B) Correlation
between outcome prediction errors and blood oxygen level-dependent activity in the two different drug states. Data in the ‘ON’ state was
averaged across the two acquisition sessions performed in the scanner under this medication state and data in the ‘OFF’ state across the
four acquisition sessions performed in this medication state. Error bars represent SEM. n.s. = not signiﬁcant.
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and avoiding the worst, stimulus within the novel pairings.
Interestingly, being in the ON dopamine replacement therapy state
during the performance phase selectively improved accuracy in
selecting the best stimulus compared to avoiding the worst stimulus
for novel stimuli pairs [paired t-tests comparing ON accuracy for
picking the best compared with avoiding worse stimulus
t(1,12) = 2.16, P = 0.05]. This performance difference between
selecting the best and avoiding the worst stimulus was not evident
when subjects both acquired and performed the task in the OFF
medication state [paired t-tests comparing OFF accuracy for picked
best compared with avoiding worse stimulus t(1,12) = 0.58,
P = 0.56], although their overall performance was worse (Fig. 4).
Of note, there was no interaction between the medication status
(ON versus OFF) during performance and the ability to pick the
best compared with avoiding the worst stimulus as has previously
been reported (Frank et al., 2004, 2007b). We only found this se-
lective improvement in picking the best stimulus compared with
avoiding the worst stimulus within the ON group. We observed the
same pattern when analysing the ON–ON and OFF–ON groups sep-
arately.However,althoughatrendwas evidentthisdidnotreachfull
signiﬁcance [paired t-tests comparing ON accuracy for picking the
best compared with avoiding worse stimulus in the ON–ON group
alone, t(1,12) = 1.5, P = 0.15; and in the OFF–ON group alone,
t(1,12) = 1.68, P = 0.11]. When we separately compared accuracy
for picking the best stimuli, and for avoiding the worst stimuli, across
groups there were no signiﬁcant differences [paired t-tests compar-
ing ‘pick best’ accuracy; ON–ON with OFF–ON, t(1,12) = 0.26,
P = 0.98; comparing ON–ON with OFF–OFF, t(1,12) = 1.79,
P = 0.09; comparing OFF–ON with OFF–OFF, t(1,12) = 1.73,
P = 0.1; paired t-tests comparing ‘avoid worse’ accuracy: ON–ON
with OFF–ON, t(1,12) = 0.07, P = 0.94; comparing ON–ON with
OFF–OFF, t(1,12) = 1.27, P = 0.22; comparing OFF–ON with
OFF–OFF, t(1,12) = 1.6, P = 0.13]. This indicates that when subjects
were ON dopaminergic medication there was an asymmetry in
performance between picking the best compared with avoiding the
worst stimuli. Our data do not show that medication selectively
improves generalization only for the best stimuli but rather that it
affects the ability to generalize learnt information overall. When we
examined reaction times, we found that across all groups there was a
signiﬁcant difference in reaction times between pick best and avoid
worse stimuli trials [paired t-test, t(1,12) = 2.52, P = 0.027] with
subjects being faster for the pick best trials. There were, however, no
signiﬁcant between group differences in reaction times.
Neuroimaging data
To investigate possible neural mechanisms underlying the observed
behavioural effects during the performance phase, we next tested for
differences in the degreeatwhich functional MRI blood oxygenlevel-
dependent activity correlated with decision variables between differ-
ent drug states. We testedwhether neural representations of stimulus
values at the time of cue presentation differed between drug states.
We found that blood oxygen level-dependent activity in nucleus
accumbens (central coordinates x =8 , y =1 2 , z = 4) correlated
with the value of the chosen cue, but this effect was only evident in
the ON medication state for correct novel trials [one sample t-test,
t(1,11) = 2.7, P = 0.01]. Cue-evoked blood oxygen level-dependent
activity did not correlate with the value of the chosen cue when
patients were OFF their dopamine replacement therapy [one sample
t-test, t(1,11) = 0.98, P = 0.34] or made an incorrect choice [one
sample t-test ON incorrect, t(1,11) = 2.12, P =0 . 0 6 ;O F Fi n c o r r e c t
t(1,11) = 0.06, P = 0.94] (Fig. 5A and B). We found an identical
effect in ventromedial prefrontal cortex (x = 2, y =3 8 , z =0 ) ,
where blood oxygen level-dependent activity varied with the value
ofthe chosencue whenpatientswerebothONmedication and made
the correct choice [one sample t-test, t(1,11) = 2.52, P = 0.02], but
Figure 3 Accuracy during performance phase. (A) Accuracy in novel pairings was signiﬁcantly higher when subjects were ON dopamine
replacement therapy during the performance phase than when they were OFF. This effect is independent of drug state during the previous
acquisition phase. Shown is the combined accuracy in selecting the best stimulus and avoiding the worst stimulus over the three drug
states when subjects had to pick the stimulus with the highest likelihood of being correct when presented in novel parings. ON–ON session
(blue), when patients took their usual dopamine replacement therapy; OFF–ON session (blue/red stripe), when patients took their
dopamine replacement therapy only after completing the acquisition phase; OFF–OFF session (red), when patients abstained from their
dopamine replacement therapy throughout the task. (B) Accuracy in selecting the better stimulus among the training pairs during the
performance phase did not differ between drug states. n.s. = not signiﬁcant.
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sample t-test, t(1,11) = 0.31, P = 0.76], or made an incorrect choice
[one sample t-test ON incorrect, t(1,11) = 1.28, P = 0.22; OFF
incorrect t(1,11) = 0.76, P = 0.46] (Fig. 5C and D). These ﬁndings
show that activity in nucleus accumbens and ventromedial prefrontal
cortexsuccessfullyreﬂectthevaluesofthemostrewardingcueonlyin
anONmedicationstate,acharacteristicthatpreciselymirrorspatients’
improved performance in this state. We foundthat this effect was not
driven solely by the ON–ON group. When the OFF–ON group are
examined separately, cue-evoked blood oxygen level-dependent
activity correlated with the value of the chosen cue with patients
made the correct choice both in the nucleus accumbens [one sample
t-test, t(1,11) = 2.86, P = 0.015] and in the ventromedial prefrontal
cortex [one sample t-test, t(1,11) = 2.93 P = 0.014], however, when
we directly compared the activations in OFF–ON with the OFF–OFF
groupthisdidnotreachstatisticalsigniﬁcance[pairedt-testcomparing
OFF–ON with OFF–OFF, nucleus accumbens t(1,11) = 1.62,
P = 0.13, ventromedial prefrontal cortex t(1,11) = 1.02, P = 0.32].
Akin to the neuroimaging ﬁndings from the acquisition phase,
when we examined value-related neural activity at the time of cue
onset during presentation of the training pairs at the performance
phase, we did not ﬁnd a signiﬁcant correlation between blood
oxygen level-dependent activity and the value of the chosen cue
in either of the drug states.
Discussion
We show a striking effect of dopamine replacement therapy on
the ability of patients with Parkinson’s disease to select the correct
stimulus in a probabilistic reinforcement learning task. Importantly,
our data show that medication status at the acquisition task phase
does not impact successful task learning. Instead, the data show
that the critical factor is medication status at the performance
phase, by which time stimulus values must already have been
successfully acquired. The ﬁndings challenge a proposal that the
impact of dopaminergic status on this form of decision-making
solely reﬂects its involvement in learning.
Our key observation was that patients who were OFF dopamine
during the second task phase performed signiﬁcantly worse when
stimuli occurred in novel pairings. However, dopaminergic drug
state did not impact their ability to choose when confronted with
pairs on which they had been trained in the ﬁrst phase of the task.
This indicates that the subjects OFF medication could successfully
retrieve learnt contingencies but were unable to use this knowledge
to make correct choices when they had to select between novel
stimulus pairings. There was no difference in learning rates or
accuracy during the acquisition phase between the different drug
conditions, indicating that dopamine did not affect the ability to
learn stimulus values. Consequently, our data indicate that dopa-
mine replacement therapy inﬂuenced the ability to generalize, in a
context, where subjects needed to select the best stimulus in a state
characterized by presentation of novel pairings.
A mechanistic basis for our behavioural ﬁndings is provided by
our functional MRI data, which speciﬁcally addressed the neural
representation of stimulus value during the performance phase.
Even when subjects had learned stimuli OFF dopamine replacement
therapy, and were only given their dopamine replacement therapy
after learning had occurred, activity in nucleus accumbens and
ventromedial prefrontal cortex encoded the value of the chosen
stimulus during the performance phase, allowing the brain to com-
pare those values in novel pairings. This suggests that, in contrast
Figure 4 Differences in accuracy at picking best compared with avoiding worst stimuli. ON state during performance phase selectively
improved accuracy for picking the best stimulus (the 80%) compared to avoiding the worst stimulus (the 20% stimulus) in novel pairings.
The data in the ‘ON’ state comes from the two performance bouts performed in this medication state and the data in the ‘OFF’ state
comes from the single performance bout performed in this medication state.
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Bayer and Glimcher, 2005; Pessiglione et al., 2006), reduced dopa-
mine availability during learning did not impair value acquisition.
Instead, our data show that decreased dopamine during perform-
ance resulted in an impoverished neural representation of stimulus
value. This we suggest impaired an ability to compare cue values in
novel pairings, in other words to generalize from learnt information.
On the other hand, non-novel pairings (i.e. the acquisition pairs)
could still be answered correctly if a stimulus–response association
had been learned; this would not depend directly on value repre-
sentations [and could for example be achieved by ﬁxed stimulus–
response associations, or explicit (episodic) memory retrieval], and
could therefore operate successfully even when dopamine levels
were low. This explanation best accounts for why subjects who
were OFF medication throughout the task were equally successful
at choosing the best stimuli in the context of the training pairs. It is
of interest that the two structures highlighted in our data, the
nucleus accumbens and ventromedial prefrontal cortex, are strongly
associated with various forms of value prediction and prediction
errors in reinforcement learning contexts (Matsumoto et al.,
2003; Day and Carelli, 2007; Luk and Wallis, 2009). The pattern
of ﬁndings we observed, whereby stimulus value correlated with
activity in these two regions in the ON state, implies that these
brain areas can successfully represent the reward value of cues
when patients are ON medication enabling successful performance
for novel pairings. However, when this signal is degraded as seen in
the OFF state, performance is impaired.
The fact that patients in all three drug states performed equally
well when they were selecting the best cue for sets on which they
had been previously trained further indicates that dopamine did
not inﬂuence patients’ accuracy by a direct inﬂuence on learning.
Levodopa medication in patients with Parkinson’s disease has
previously been shown to have a positive effect on generalization
of learnt information in novel contexts; however, those observa-
tions were on a background of impaired learning and therefore
crucially different from our current ﬁndings (Myers et al., 2003;
Shohamy et al., 2006). Of course, many different systems are
likely to be involved in learning, only some of which depend
directly on dopamine (Beninger, 1983; Dickinson et al., 2000;
Daw et al., 2005; Palmiter, 2008), and we cannot discount the
Figure 5 Brain activity correlating with the value of the chosen cue during performance phase. (A) Brain activity in right nucleus
accumbens (R NAc) correlated with the value of the chosen cue. Analysis performed over all correct trials (both ON and OFF) in a context
where novel parings are presented. (B) A differential analysis between drug states reveals this correlation was selective to the ON state.
(C) Brain activity in ventromedial prefrontal cortex (vmPFC) also correlated with the value of the chosen cue. Whole brain analysis
performed over all correct trials (both ON and OFF). (D) Similar to activity in nucleus accumbens, the correlation between blood oxygen
level-dependent values in ventromedial prefrontal cortex and the value of the chosen cue was only evident in ON but not in OFF state.
The error bars represent SEM. Thresholds in statistical parametric map images set to P50.005 uncorrected.
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ving sequences of choices, might be necessary to fully reveal
effects of dopamine on learning.
Beyond its putative role in learning, dopamine is implicated in a
number of distinct processes related to motivation, including the con-
trol of Pavlovian conditioned responses and motivational vigour
(Dickinson et al., 2000; Parkinson, et al., 2002; Salamone et al.,
2003; Berridge, 2007; Mazzoni et al., 2007; Niv, 2007; Bardgett
et al., 2009; Beeler et al., 2010; Boureau and Dayan, 2011). The
strong inﬂuence of dopamine on performance, separate to that on
learning, is well known from animal data. For example, dopamine-
deﬁcient mice retain the ability to pick the most rewarding drink
(sucrose compared with water) when presented in a discrimination
task (Cannon and Palmiter, 2003). Genetic dopamine-deﬁcient mice
when tested in a maze task appears initially impaired but when subse-
quently treated with L-DOPA (Robinson et al., 2005), or caffeine
(Hnasko et al., 2005) can be shown to have learned, consistent with
an effect of dopamine on the expression of learning rather than on
learning itself. In addition,dopamine isimplicated in controlling move-
ment rate and vigour (Ungerstedt, 1971; Salamone et al., 2003;
Cagniard et al., 2006) with dopamine depletion causing decreased
motivation to work for rewards under demanding reinforcement
schedules (Salamone and Correa, 2002; Niv, 2007).
Importantly, these other roles remain consistent with the fact
that phasic activity of dopamine neurons codes for an appetitive
prediction error (McClure et al., 2003). However, our study has
enabled us to disentangle these effects from a mere effect on
learning in a manner that provides compelling evidence that dopa-
mine has a speciﬁc role on the expression of learning that is
distinct from any effect it may have on learning itself. We are,
however, unable to comment on whether the drug manipulation,
which included the withdrawal and then reinstatement of both
L-DOPA and dopamine agonists, primarily exerted its main effect
on tonic or phasic levels of dopamine although we infer that it is
likely to have an effect on both.
The involvement of the nucleus accumbens during successful per-
formance is particularly notable, since this structure is well known to
control the immediate effects of dopamine on numerous aspects of
performance (Berridge and Robinson, 1998; Ikemoto and Panksepp,
1999; Berridge, 2009; Lex and Hauber, 2010). The nucleus accum-
bens is a site where the predicted values of stimuli are transformed
into preparatory Pavlovian responses under a modulatory inﬂuence
of dopamine (Berridge and Robinson, 1998). We suggest that a
preparatory response of approach is likely to be a key substrate for
the behavioural patterns we observed in our task (Dayan et al.,
2006). This provides another reminder of the complexities inherent
in a single neuromodulator (dopamine) supporting two apparently
independent roles, namely reporting on appetitive prediction errors
and inﬂuencing motivation and vigour (Ikemoto and Panksepp,
1999;Nivetal.,2007;BoureauandDayan,2011;Coolsetal.,2011).
A further important ﬁnding is the engagement of ventromedial
prefrontal cortex in a context in which subjects made the correct
choice between novel pairings of stimuli in the ON state, but not
when subjects made incorrect choices in the ON state. This region
is strongly implicated in valuation (Gottfried et al., 2003; Seymour
and McClure, 2008; Boorman et al., 2009; Kable and Glimcher,
2009; Fitzgerald et al., 2010; Plassmann et al., 2010) across a
range of experimental manipulations, with mounting evidence
pointing to a speciﬁc role when subjects have to choose between
distinct options with different values (Padoa-Schioppa and Assad,
2006; FitzGerald et al., 2009; Wunderlich et al., 2010). This ﬁts
neatly with our observation that this region was engaged when
subjects generated correct choices based upon an assessment of a
learnt value difference between novel pairings. However, our data
are intriguing in suggesting that the integrity of a dopamine input
to this region is important for this form of value-based decision.
Of course, we cannot be certain as to dopamine’s precise role in
our task. However, two possibilities are immediately apparent:
dopamine is either necessary for a stable value representation that
can support generalization, or alternatively, for taking the difference
between the values of the available stimuli in order to choose. We
were unable to dissociate whether the neural value correlates were
precursors to choice (stimulus values) or the output of the choice
process (chosen values) (Wunderlich et al., 2009). It remains an
open question for future research as to whether the deﬁcit is due
to a misrepresentation of pre-choice values that are fed into a
decision comparator, or reﬂect a problem at the value comparison
stage itself or indeed a combination of both.
Our study involved testing patients with Parkinson’s disease,
which although providing the best human model of dopamine
depletion, there is by necessity the problem of whether observa-
tions in this population can be generalized to the healthy popula-
tion. Despite this caveat, our ﬁndings do lend support to the
hypotheses (Berridge and Robinson, 1998; Berridge, 2007) and
animal studies (Ahlenius et al., 1977; Beninger and Phillips,
1981; Wyvell and Berridge, 2000; Cannon and Palmiter, 2003;
Denenberg et al., 2004; Robinson et al., 2005) that stress a
major role for dopamine outside of learning.
A signiﬁcant ﬁnding from our study is that when patients were
ON their dopamine replacement therapy, they were worse at
avoiding stimuli with the poorest probabilistic contingencies than
at choosing the stimuli with the best probabilistic outcomes. This is
in keeping with previous research showing a similar outcome
valence performance asymmetry, whereby patients ON their
dopamine replacement therapy are impaired at avoiding the
least rewarding stimuli (Frank et al., 2004, 2007b). It has been
postulated that this worsening in performance is due to ‘over-
dosing’ of the striatum, which interferes with the dips in dopamine
that express negative prediction errors (Frank et al., 2004, 2007b).
However, in our study, as in several others (de Wit et al., 2011;
Jocham et al., 2011), we did not ﬁnd a direct effect of medication
on learning, and we postulate that the worsened performance
may reﬂect some other mechanism, perhaps an impaired expres-
sion of avoidance behaviour in a high dopamine state.
Of note, we did not ﬁnd the interaction between medication
state and picking the best compared with avoiding the worst stimu-
lus that has been reported in some previous studies (Frank et al.,
2004, 2007b; Voon et al., 2010). We found an overall improve-
ment in performance when subjects were ON medication and an
asymmetry in this performance accuracy between picking the best
compared with avoiding the worst stimuli within this group.
We did not ﬁnd a signiﬁcant difference between picking the
best stimulus in the ON state and picking the best stimulus in
the OFF state. Thus, although we can conclude that when subjects
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performance between picking the best compared with avoiding
the worst stimuli, we cannot be certain whether this improvement
in performance in the ON compared with the OFF group is solely
due to an improved ability to select the most rewarding stimuli.
Since the OFF–OFF patients generalized so poorly, there remains a
possibility that we were unable to detect an asymmetry in
performance in the OFF group due to ﬂoor effects. However,
the clear asymmetry observed in the ON group is of interest as
it provides a hint as to where dopamine may exert an important
inﬂuence.
Several studies have also found differences in striatal activations
in response to wins and losses when comparing patients with
Parkinson’s disease with compulsive behaviour ON medication to
patients with idiopathic Parkinson’s disease (Steeves et al., 2009;
Voon et al., 2010) or in healthy subjects who were given dopa-
minergic modulating drugs (Pessiglione et al., 2006; Cools et al.,
2007). We did not ﬁnd this pattern in our study, possibly because
of the unique feature of our design in making within-subject
comparisons in patients with idiopathic Parkinson’s disease. In par-
ticular, acute pharmacological manipulations in healthy volunteers
may have very different effects to those found in patients
previously exposed to dopaminergic agents. Another potential
explanation for these differences is that in contrast to the studies
that found differences in striatal activations in response to gains
and losses (Pessiglione et al., 2006; Bodi et al., 2009; Palminteri
et al., 2009; Voon et al., 2010), we did not have actual losses as
outcomes, only stimuli that were probabilistically more or less
likely to be correct. We caution against a conclusion that our
data indicate that prediction errors do not play an important role
in learning. Indeed, we observed prediction errors during the task
acquisition. We were, however, unable to detect differences in the
magnitude of these activations when dopaminergic drugs were
given to this patient group, consistent with a suggestion that for
successful choice, it is critical that dopamine levels are high during
actual performance. We also cannot discount the fact that there
might remain some residual activity within the dopaminergic
system of patients with Parkinson’s disease, resulting in adequate
levels of dopamine to signal reward prediction errors in some
structures, but not enough to form adequate cue value represen-
tations to allow successful generalization in those, or other, struc-
tures. Furthermore, in some contexts the relationship between
dopamine appears to follow an inverted U-shaped function
whereby the optimum level of performance exists at a certain
level of dopaminergic stimulation and moving off that peak,
either by reducing or increasing the levels of dopamine, leads to
worsened task performance (Robbins, 2000; Rowe et al., 2008;
Cools and D’Esposito, 2011) rendering dopaminergic manipula-
tions crucially dependant on baseline levels. There is a possibility
that high level of cognitive processing, such as working memory,
required for this task may obscure differences in striatal activa-
tions. Indeed, differing performance in tasks of this type has
been shown in genetic studies to have a differential impact on
prefrontal and striatal dopamine (Frank et al., 2007a; Klein
et al., 2007). However, in our task if dopamine had in fact
boosted the prediction error magnitude in a way that impacted
learning, we would have expected to see this in improved
behaviour in the performance phase. This would result in the
ON–ON group performing the best, which was in fact not the
case.
By teasing apart learning and performance in patients with
Parkinson’s disease, we found that dopaminergic medication im-
pacted the latter, but not the former. At the neural level, this
improved performance in the ON medication state was associated
with enhanced nucleus accumbens and ventromedial prefrontal
cortex activity for the chosen cue value, an effect that was
absent in the OFF medication state. Thus, the improved perform-
ance in patients ON medication cannot solely be attributed to an
effect on learning and must reﬂect some other effect of dopamine,
perhaps Pavlovian appetitive approach or a modulation of the
motivational impact of cues associated with improved neural
representation of cue value in a high dopamine state. By isolating
the processes on which dopamine has the greatest impact, our
ﬁndings point to likely mechanisms that underlie common behav-
ioural deﬁcits seen in patients with Parkinson’s disease, both
clinically and in various laboratory tasks, as well as providing a
basis for future cognitive-oriented therapies.
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